1. Home
  2. SYRA vs BCDA Comparison

SYRA vs BCDA Comparison

Compare SYRA & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYRA
  • BCDA
  • Stock Information
  • Founded
  • SYRA 2020
  • BCDA N/A
  • Country
  • SYRA United States
  • BCDA United States
  • Employees
  • SYRA N/A
  • BCDA N/A
  • Industry
  • SYRA Other Specialty Stores
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SYRA Industrials
  • BCDA Health Care
  • Exchange
  • SYRA Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • SYRA 8.5M
  • BCDA 9.4M
  • IPO Year
  • SYRA 2023
  • BCDA N/A
  • Fundamental
  • Price
  • SYRA $1.35
  • BCDA $3.11
  • Analyst Decision
  • SYRA
  • BCDA Strong Buy
  • Analyst Count
  • SYRA 0
  • BCDA 1
  • Target Price
  • SYRA N/A
  • BCDA $60.00
  • AVG Volume (30 Days)
  • SYRA 50.9K
  • BCDA 63.4K
  • Earning Date
  • SYRA 08-13-2024
  • BCDA 08-07-2024
  • Dividend Yield
  • SYRA N/A
  • BCDA N/A
  • EPS Growth
  • SYRA N/A
  • BCDA N/A
  • EPS
  • SYRA N/A
  • BCDA N/A
  • Revenue
  • SYRA $6,079,133.00
  • BCDA $468,000.00
  • Revenue This Year
  • SYRA $70.86
  • BCDA N/A
  • Revenue Next Year
  • SYRA N/A
  • BCDA $436.41
  • P/E Ratio
  • SYRA N/A
  • BCDA N/A
  • Revenue Growth
  • SYRA 3.73
  • BCDA N/A
  • 52 Week Low
  • SYRA $0.81
  • BCDA $2.62
  • 52 Week High
  • SYRA $8.37
  • BCDA $41.55
  • Technical
  • Relative Strength Index (RSI)
  • SYRA 45.79
  • BCDA 37.71
  • Support Level
  • SYRA $1.30
  • BCDA $2.62
  • Resistance Level
  • SYRA $1.37
  • BCDA $3.15
  • Average True Range (ATR)
  • SYRA 0.07
  • BCDA 0.29
  • MACD
  • SYRA -0.00
  • BCDA 0.10
  • Stochastic Oscillator
  • SYRA 41.18
  • BCDA 65.79

About SYRA Syra Health Corp.

Syra Health Corp is a healthcare services company promoting preventative health, holistic wellness, health education, and equitable healthcare for all patient demographics. The company leverages deep scientific and healthcare expertise to create strategic frameworks and develop patient-centric solutions for the betterment of patient lives and health outcome linked to developing a healthier population. It strives to offer comprehensive end-to-end solutions in health education services, population health management, behavioral and mental health, healthcare workforce and digital health.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: